Benzinga's Top Upgrades
Analysts at Cantor Fitzgerald upgraded Aetna Inc (NYSE: AET) from Hold to Buy. The price target for Aetna has been raised from $100 to $140. Aetna shares closed at $117.75 on Thursday.
Analysts at Cowen & Company upgraded FMC Corp (NYSE: FMC) from Market Perform to Outperform. FMC shares closed at $38.79 on Thursday.
Analysts at JP Morgan upgraded The Valspar Corp (NYSE: VAL) from Neutral to Overweight. The price target for Valspar has been raised from $82 to $83. Valspar shares closed at $74.91 on Thursday.
Credit Suisse upgraded Dillard's, Inc. (NYSE: DDS) to Neutral. The price target for Dillard's has been lowered from $100 to $95. Dillard's shares closed at $92.30 on Thursday.
Raymond James upgraded Goldman Sachs BDC Inc (NYSE: GSBD) from Market Perform to Outperform. Goldman Sachs BDC shares closed at $20.22 on Thursday.
Analysts at RBC Capital upgraded Core Laboratories N.V. (NYSE: CLB) from Sector Perform to Outperform. The price target for Core Laboratories has been raised from $125 to $130. Core Laboratories shares closed at $108.74 on Thursday.
UBS upgraded PPL Corp (NYSE: PPL) from Neutral to Buy. The price target for PPL has been lowered from $34 to $33. PPL shares closed at $30.79 on Thursday.
Latest Ratings for AET
|Jan 2017||Leerink Swann||Downgrades||Outperform||Market Perform|
|Jan 2017||PiperJaffray||Initiates Coverage On||Neutral|
|Nov 2016||Credit Suisse||Upgrades||Neutral||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.